Disease Atlas / Disease detail
Accessible educational material explaining the causes, symptoms, diagnosis, management, and research questions of megalencephalic leukoencephalopathy.
leukoencephalopathy, megalencephalic
Start with the essentials, then explore the patient and research views.
Public revision · 3104e3e1fa81
A structured guide for understanding the disease and preparing for clinical conversations.
Megalencephalic leukoencephalopathy is a rare inherited white matter disorder in which the brain is enlarged and the white matter is abnormal, sometimes with subcortical cysts.
In infancy or childhood, an increasing head circumference, delayed motor development, ataxia, low muscle tone, or spasticity may occur.
Megalencephalic leukoencephalopathy is mainly caused by variants related to MLC1 or HEPACAM and is usually inherited in an autosomal recessive pattern.
Abnormalities of the associated proteins are understood to affect the structure and water regulation of the brain's white matter, contributing to white matter changes and the formation of subcortical cysts.
Family history and whether both parents are carriers are relevant to risk, while the timing and severity of symptoms may differ with the genetic variant and each person's disease course.
The course is generally slowly progressive, but function may worsen after head trauma or infection, and cognition may remain relatively preserved into adulthood in some people.
Diagnosis is based on the medical history and neurological assessment, identification of characteristic white matter changes and subcortical cysts on brain MRI, and genetic testing when needed for support.
MRI findings alone cannot confirm the diagnosis; similar white matter disorders and cystic lesions must be distinguished, while the limitations of testing methods and variant interpretation are also considered.
Management involves assessing motor, cognitive, and communication function while coordinating rehabilitation, control of symptoms such as seizures and spasticity, safety measures, and support for daily activities.
No standard treatment has been established that reliably stops or reverses disease progression, so treatment aims to preserve function and manage complications.
Follow-up should record individual changes in motor and cognitive function, seizures, vision and hearing, and MRI findings; registration of a clinical trial does not establish efficacy, approval, or standard-of-care status.
During clinical care, it is important to review symptom onset and episodes of deterioration, changes in seizures, movement, and learning, family history, the MRI follow-up plan, and the need for genetic testing and family counseling.
This material is for educational purposes and is not a guide for individual diagnosis or treatment.
A trial registry status does not establish efficacy or regulatory approval.
MONDO · ONTOLOGY